Vanda Signs a Collaboration with UW Medicine to Initiate CALYPSO Program for Evaluating the Role of Genetic Variation in COVID-19

 Vanda Signs a Collaboration with UW Medicine to Initiate CALYPSO Program for Evaluating the Role of Genetic Variation in COVID-19

Vanda Signs a Collaboration with UW Medicine to Initiate CALYPSO Program for Evaluating the Role of Genetic Variation in COVID-19

Shots:

  • Vanda will collaborate with UW Medicine and its Virology Lab on a pharmacogenetics study in patients with COVID-19. The study will focus on the sequencing of the genome of individual patients, as well as the COVID-19 virus, and the identification of genetic factors that correlate with disease progression and outcomes
  • To support the study, Vanda and UW Medicine plan to collect WGS data from 1,000+ patients with COVID-19 infection and perform Viral Genome Sequencing, which enables them to explore host susceptibility, associations of WGS with clinical outcomes and severity of the disease, as well as host-virus interactions
  • The study is expected to initiate the enrollment in the coming weeks and will be open to patients in hospitals and clinics around the US

Click here ­to­ read full press release/ article | Ref: Vanda | Image: Vanda

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post